Formulation and Development of Buccaleffervescent Tablets of Silodosin
Main Article Content
Abstract
The present work was attempted to formulate and development of Buccal Effervescent tablets of Silodosin by Direct Compression method. Literature survey was carried out for selection of suitable excipients. Pre-formulation studies were conducted to identify Silodosin by means of UV Spectrophotometric test and melting point determination. The results of compatibility studies were carried out by FTIR. The result of FTIR analysis showed compatibility without any significant interaction all pre-compression parameter like Carr’s index, Hausner’s ratio and Angle of repose. The average Wight, friability and Hardness were within compendial limits which showed that all formulation possessed good mechanical strength. Optimized formulation showed minimum Effervescent time of 65.52±0.3sec, disintegration time 77.95±0.53sec. The batch showed that there was no significant change in Hardness, wetting time, In-vitro Disintegration time, Drug content, and In-vitro Dissolution profile for a period of one mouth when Stability study for period of one mouth. From the study it was concluded that Buccal Effervescent Tablets of Silodosin can be successfully prepared using Effervescent agent by direct compress method which can provide time. Thus, it will be an important factor in improving patient compliance which is prerequisite for the treatment of Prostate gland for all age groups.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Suryawanshi KA, Erande KB, Patil DP, Bachhav YS, Nahar PP, Bagad SP, et al. Formulation of Eudragit-based sulfasalazine nanosuspension with enhanced drug encapsulation. Int J Drug Deliv Technol. 2026;16(9s):957-967. doi:10.25258/IJDDT.16.9s.100.
Nahar PP, Patil DP, Malik Md MR, Chavan MD, Jagtap SD. Optimization of ritonavir preformulation: techniques and approaches for enhancing drug formulation. Biosci Biotechnol Res Asia. 2024;21(4):1625-1632.
Bhambar KV, Nikam AP, Newadkar PT, Bachhav YS, Aher RS, Suryawanshi KA. Development and validation of an RP-HPLC method for simultaneous estimation of azelnidipine and chlorthalidone in bulk and fixed-dose combination using analytical quality by design with greenness assessment. Int J Drug Deliv Technol [Internet]. 2026 Apr 29 16(21s).
Hasan MA, et al. Development of a convenient and robust analytical technique for HPLC-based determination of silodosin in capsule formulation. Res J Pharm Technol. 2024;17(9):4311-4317.
Mishra S, Ninama S, Chauhan A. Development and validation of stability-indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture. Ann Pharm Fr. 2024;82(2).
Abdel Moneim M. Simultaneous spectrophotometric and spectrofluorimetric assay of silodosin and solifenacin in their co-formulated binary mixture. J Adv Pharm Res. 2023;7(1):15-20.
Wadie M, et al. A green and versatile HPLC-DAD method for determination of silodosin and solifenacin in their newly combined formulation: evaluation of content uniformity and dissolution profiles. Sustain Chem Pharm. 2025;44:101923.
Dhiman S, Kurmi BD, Asati V. Analytical reversed-phase high-performance liquid chromatography method development for silodosin and solifenacin in bulk and marketed formulation using analytical quality by design approach. Sep Sci Plus. 2023;6(2):2200117.
Alhayali A, Vuddanda PR, Velaga S. Silodosin oral films: development, physico-mechanical properties and in vitro dissolution studies in simulated saliva. J Drug Deliv Sci Technol. 2019; 53:101122.
Montorsi F. Profile of silodosin. Eur Urol Suppl. 2010;9(4):491-495.
Sebastine IM, Wakeman RJ. Consumption and environmental hazards of pharmaceutical substances in the UK. Process Saf Environ Prot. 2003;81(4):229-235.
Roy SB. Pharmaceutical compositions of silodosin [Internet]. 2013 May. Patent No.: WO2013061338A1. Available from: https://patents.google.com/patent/WO2013061338A1/en
Villa L, et al. Silodosin: an update on efficacy, safety and clinical indications in urology. Adv Ther. 2019;36:1-18.
Rossi M, Roumeguère T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010:291-297.
Luo J, Wang X, Xie L. Evolving role of silodosin for the treatment of urological disorders: a narrative review. Drug Des Devel Ther. 2023:2861-2884.
Cantrell MA, et al. New drug approvals: silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010;44(2):302-310.
Meisner M, et al. Characteristics of commercial effervescent tablets using selected pharmacopeial and novel analytical methods. Appl Sci. 2023;13(5):3171.
Ferrari BJW, et al. Formulation and in vivo study of the solid effervescent system as a new strategy for oral glutamine delivery. J Drug Deliv Sci Technol. 2021;63:102516.
Taymouri S, Mostafavi A, Zaretaghiabadi S. Design, formulation and evaluation of physicochemical properties of valacyclovir effervescent tablet. Trends Pharm Sci. 2022;8(3):135-146.
Arévalo JFB, Pérez YEL, Rojas J. Production of an effervescent powder from Solanum betaceum fruit having enhanced antioxidant properties. J Food Nutr Res. 2021;9(3):108-113.
Smail SS, Ibrahim NJ, Hussein NR. Development and in vitro evaluation of buccal effervescent tablet containing ropinirole hydrochloride. Polytech J. 2019;9(2):7.
Aslani A, Jahangiri H. Formulation, characterization and physicochemical evaluation of ranitidine effervescent tablets. Adv Pharm Bull. 2013;3(2):315.
Aslani A, Sharifian T. Formulation, characterization and physicochemical evaluation of amoxicillin effervescent tablets. Adv Biomed Res. 2014;3(1):209.
Srinath KR, et al. Formulation and evaluation of effervescent tablets of paracetamol. Int J Pharm Res Dev. 2011;3(3):76-104.
Mhaske GA, et al. A review on effervescent tablet. 2024.
Jaipal A, et al. Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies. Drug Deliv. 2016;23(2):452-458..